Skip to main content
. 2022 Jun 21;9:891434. doi: 10.3389/fmed.2022.891434

FIGURE 2.

FIGURE 2

Photographs of three representative patients in the three groups. (A) Patient in the SCs group with the SALT score of 100% prior to treatment and 0% after 18 months of treatment. (B) Patient in the tofacitinib group with the SALT score of 75% prior to treatment and 0% after 7 months of treatment. (C) Patient in the combined group with the SALT score of 100% prior to treatment and 0% after 31 months of treatment.